	US 11,697,796 B2
	Media and methods for enhancing the survival and proliferation of stem cells
Adam Hirst, Vancouver (CA); Arwen Hunter, Vancouver (CA); Melanie Kardel, Vancouver (CA); and Wing Chang, Vancouver (CA)
Assigned to STEMCELL TECHNOLOGIES CANADA INC., Vancouver (CA)
Appl. No. 16/480,025
Filed by STEMCELL Technologies Canada Inc., Vancouver (CA)
PCT Filed Jan. 23, 2018, PCT No. PCT/CA2018/050076 § 371(c)(1), (2) Date Jul. 23, 2019, PCT Pub. No. WO2018/132926, PCT Pub. Date Jul. 26, 2018.
Claims priority of provisional application 62/608,875, filed on Dec. 21, 2017.
Claims priority of provisional application 62/518,776, filed on Jun. 13, 2017.
Claims priority of provisional application 62/449,413, filed on Jan. 23, 2017.
Prior Publication US 2020/0017825 A1, Jan. 16, 2020
Int. Cl. C12N 5/0735 (2010.01); C12N 5/074 (2010.01)

CPC C12N 5/0606 (2013.01) [C12N 5/0696 (2013.01); C12N 2500/36 (2013.01); C12N 2501/115 (2013.01); C12N 2501/15 (2013.01); C12N 2501/727 (2013.01); C12N 2501/999 (2013.01); C12N 2533/90 (2013.01)]

12 Claims

1. A cloning supplement comprising one or more small molecule inhibitors and two or more lipids in the presence of a carrier, wherein

the carrier is an agent, substance, composition or complex that transports some or all of the two or more lipids to a mammalian pluripotent stem cell,

the two or more lipids comprise oleic acid and palmitic acid,

the amount of each alpha-linolenic acid and/or arachidonic acid is less than 300 μg per gram of carrier, and

wherein the survival or proliferation of mammalian pluripotent stem cells is enhanced in a culture medium containing the supplement as compared to a culture medium that does not contain the supplement.